AMENDMENTS TO THE CLAIMS

1-20. (Cancelled).

21. **(Currently Amended)** A compound of the following formula (1):



in which m and n each independently represents ~~1 or~~ 2,

R^1 represents

hydrogen;

heterocycle which is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and which is unsubstituted, or mono- or polysubstituted by substituents selected from halogen and C_1-C_{10}-alkyl;

-$(CH_2)_{1-3}$-R^6, wherein R^6 is selected from the group consisting of hydrogen, C_1-C_{10}-alkyl, C_1-C_8-alkoxy, heterocycle, hydroxy, C_1-C_8-alkoxylcarbonyl, carboxy, amino, C_1-C_{10}-alkylamino, di(C_1-C_{10}-alkyl)amino, and C_1-C_8-alkylcarbonylamino[[;]], wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl and C_6-C_{10}-aryloxy;

glycine, alanine, histidine, phenylalanine or proline[[;]], wherein one or more hydrogen atoms on nitrogen atom are unsubstituted or substituted by a substituent selected from the group consisting of C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl, C_1-C_8-alkoxycarbonyl and C_1-C_8-alkylsulfonyl; or

-SO_2-C_1-C_3-alkyl,

R^2 represents

hydrogen;

C_1-C_8-alkyl;

-CO-$(CH_2)_{1-3}$-hydroxy; or

-CH_2-CO-hydroxy,

R^3 represents

C_1-C_8-alkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from C_1-C_8-alkyl and carbamoyl;

-$(CH_2)_{1-3}$-C_3-C_8-cycloalkyl; or

-$(CH_2)_{0-3}$-C_6-C_{10}-aryl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, C_1-C_8-alkoxy and C_1-C_8-alkyl,

R^4 represents

C_1-C_8-alkyl;

-$(CH_2)_{1-3}$-C_3-C_8-cycloalkyl;

C_3-C_8-cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C_1-C_8-alkyl and C_6-C_{10}-aryl;

~~spiro[2,5]octan;~~ or

heterocycle which is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring,

R^5 represents

carbonyl substituted by a substituent selected from the group consisting of C_1-C_8-alkyl, C_1-C_6 alkoxy, C_3-C_7-cycloalkyl, heterocycle and C_6-C_{10}-aryl unsubstituted or substituted by hydroxyl[[;]], wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of amino, C_1-C_8-alkylamino, di(C_1-C_8-alkyl)amino, hydroxy, C_1-C_8-alkoxy, C_6-C_{10}-ar-C_1-C_8-alkyloxy, C_1-C_8-alkyl C_6-C_{10}-aryloxy, C_6-C_{10}-aryloxy, C_6-C_{10}-arylthio, formyl, C_2-C_8-alkanoyloxy, C_3-C_8-cycloalkylcarbonyloxy, C_6-C_{10}-arylcarbonyloxy ~~unsubsituted~~ unsubstituted or substituted by halogen, C_6-C_{10}-ar-C_1-C_8-alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group

consisting of hydroxycarbonyl, C_1-C_8-alkoxycarbonyl, hydroxyl-C_1-C_8-alkyl[[;]], and wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxyC_1-C_8-alkyl, amino and 2-nitrobenzenesulfonyl;

-$(CH_2)_{1-3}$-C(=O)-C_1-C_6-alkoxy;

carbamoyl which is mono- or polysubstituted by substituents selected from the group consisting of hydrogen, C_1-C_8-alkyl, C_1-C_6-alkoxy, C_3-C_7-cycloalkyl, C_6-C_{10}-aryl and C_1-C_8-alkylcarbonyl substituted by hydroxyl[[;]], wherein alkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, hydroxy, amino and C_1-C_8-alkoxy;

-$(CH_2)_{1-3}$-C(=O)N(C_1-C_8-alkyl)(C_1-C_8-alkyl);

-C(=S)N(H)(C_1-C_8-alkyl) or -C(=S)N(H)(C_1-C_8-alkyl)(C_1-C_8-alkyl); or

-SO_2-NH_2 or –$(CH_2)_{0-3}$-SO_2-C_1-C_8alkyl,

wherein heterocycle ~~includes 1 to 2 heteroatom(s) from the group consisting of nitrogen atom, oxygen atom and sulfur atom, and represents 4- to 8-membered ring which~~ can be fused with benzo or C_3-C_8-cycloalkyl, and which is saturated or has 1 or 2 double bond, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

22. **(Currently Amended)** The compound according to claim 21, wherein

R^1 represents

hydrogen; or

-$(CH_2)_{1-3}$-R^6, wherein R^6 selected from the group consisting of hydrogen, C_1-C_{10}-alkyl, C_1-C_8-alkoxy, heterocycle, hydroxy, C_1-C_8-alkoxylcarbonyl, carboxy, amino, C_1-C_{10}-alkylamino, di(C_1-C_{10}-alkyl)amino, and C_1-C_8-alkylcarbonylamino[[;]], wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is substituted by one or more substituents selected from the group consisting of halogen, oxo, hydroxy, C_1-C_{10}-alkyl, C_1-C_8-alkylcarbonyl and C_6-C_{10}-aryloxy; or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

23. (Previously Presented) The compound according to claim 21, wherein

R^2 represents hydrogen or C_1-C_6-alkyl, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

24. (Previously Presented) The compound according to claim 21, wherein

R^3 represents $-CH_2$-phenyl which is unsubstituted or mono- to tri-substituted by substituents selected from the group consisting of chloro, bromo, hydroxy, methoxy and methyl, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

25. (Previously Presented) The compound according to claim 21, wherein

R^4 represents C_3-C_8-cycloalkyl which is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of halogen, C_1-C_8-alkyl and C_6-C_{10}-aryl, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

26. **(Currently Amended)** The compound according to claim 21, wherein

R^5 represents carbonyl substituted by the substituent selected from the group consisting of C_1-C_8-alkyl, C_1-C_6-alkoxy, C_3-C_7-cycloalkyl, heterocycle and C_6-C_{10}-aryl unsubstituted or substituted by hydroxyl[[;]], wherein alkyl is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of amino, C_1-C_6-alkylamino, di(C_1-C_6-alkyl)amino, hydroxy, C_1-C_8-alkoxy, C_6-C_{10}-ar C_1-C_8-alkyloxy, C_1-C_8-alkyl C_6-C_{10}-aryloxy, C_6-C_{10}-aryloxy, C_6-C_{10}-arylthio, formyl, C_2-C_8-alkanoyloxy, C_3-C_8-cycloalkylcarbonyloxy, C_6-C_{10}-arylcarbonyloxy ~~unsubsituted~~ unsubstituted or substituted by halogen, C_6-C_{10}-ar-C_1-C_8-alkylcarbonyloxy; cycloalkyl is unsubstituted, or mono- or polysubstituted by substituents selected from the group consisting of hydroxycarbonyl, C_1-C_8-alkoxycarbonyl, hydroxyl- C_1-C_8-alkyl[[;]], and wherein heterocycle is selected from the group consisting of morpholine, pyrrolidine, piperidine, furan and tetrahydroisoquinoline ring and is unsubstituted, or mono- or polysubstituted by the substituents selected from the group consisting of hydroxy, hydroxyC_1-C_8-alkyl, amino and 2-nitrobenzenesulfonyl, or

a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof.

27. (Previously Presented) An agonistic composition of melanocortin receptor comprising the compound of formula (1), or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof as defined in claim 21 together with a pharmaceutically acceptable carrier.